Literature DB >> 27084087

Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood.

Bertrand Degos1, Yann Nadjar1, Maria del Mar Amador1, Foudil Lamari2,3,4, Frédéric Sedel5, Emmanuel Roze1,6, Philippe Couvert7, Fanny Mochel8,9,10,11.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is among the few inherited neurometabolic disorders amenable to specific treatment. It is easily diagnosed using plasma cholestanol. We wished to delineate the natural history of the most common neurological and non-neurological symptoms in thirteen patients with CTX. Diarrhea almost always developed within the first year of life. Cataract and school difficulties usually occurred between 5 and 15 years of age preceding by years the onset of motor or psychiatric symptoms. The median age at diagnosis was 24.5 years old. It appears critical to raise awareness about CTX among paediatricians in order to initiate treatment before irreversible damage occurs.

Entities:  

Keywords:  Cataract; Cerebellar ataxia; Cerebrotendinous xanthomatosis; Cognitive dysfunction; Diarrhea; Psychiatric symptoms

Mesh:

Year:  2016        PMID: 27084087      PMCID: PMC4833925          DOI: 10.1186/s13023-016-0419-x

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


Introduction

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive sterols storage disorder caused by 27-sterol-hydroxylase deficiency due to CYP27A1 mutations resulting in an accumulation of cholestanol in blood and organs, mainly the central nervous system, eyes, tendons and vessels [1, 2]. With an estimated prevalence of 1/50,000 [3] but only about 300 patients reported, CTX remains too often under- or misdiagnosed while treatment is available. Patients typically manifest both systemic and neuropsychiatric symptoms of the disease. Systemic manifestations may include infantile cholestasis or liver dysfunction, juvenile cataract, Achilles tendon xanthomas, osteoporosis, premature arteriosclerosis and cardiovascular disease [1, 2, 4]. Neurological symptoms encompass cognitive delay, spastic paraplegia, cerebellar ataxia, peripheral neuropathy, bulbar palsy, epilepsy, movement disorders, dementia and psychiatric disturbances [1, 2, 4]. While these symptoms are well described, their natural history is not. More importantly, CTX is almost always diagnosed in adults whereas most of the initial symptoms occur in childhood and adolescence. We therefore describe the natural history of the most common neurological and non-neurological symptoms in thirteen patients with CTX in order to alert on the early symptoms of the disease.

Patients and methods

We collected retrospectively clinical, biochemical, imaging and electrophysiological data from thirteen genetically confirmed CTX patients followed at La Pitié-Salpêtrière University Hospital. In order to delineate the natural history of the disease, we selected only patients whose diagnosis was made in adolescence or adulthood. Values are expressed in mean ± SD and/or median. For the Kaplan-Meier analyses, we assumed that patients are determined to have CTX at birth. Therefore all time to event data (e.g. time to diarrhea, time to cataract) assumed that the initial time was the date of birth. The censoring time was the age at latest neurological exam. The symptoms were communicated via the caregiver or the patient directly. Each patient gave a written informed consent to participate in the study. The study was approved by the local ethics committee (CPPIdF6, La Pitié-Salpêtrière University Hospital).

Results

We describe four males and nine females with CTX belonging to ten families. Four patients were born from a consanguineous union (Additional file 1). All patients were Caucasian except two patients of Turkish origin. Six patients were compound heterozygous and five patients homozygous for CYP27A1 mutations. In two siblings, the second mutation was not identified despite very high levels of plasma cholestanol (Additional file 1). In three families, the diagnosis of the index case led to the diagnosis of a sibling. The mean and median age at diagnosis were 30.4 ± 14.9 years and 24.5 years (range: 14-55) respectively. The mean and median disease duration at the time of diagnosis were 26.2 ± 11.6 years and 21.5 years (range: 13.5–54.5) respectively. The natural history of our CTX cohort revealed that chronic diarrhea was very common, starting within the first year of life (Table 1, Fig. 1). None of our patients had a known history of infantile hepatic dysfunction. Cataract and school difficulties usually followed between 5 and 15 years of age (Additional file 1). Another 5–15 years later, most patients developed motor dysfunction leading to walking difficulties and/or psychiatric symptoms (Fig. 1, Additional file 1). Plasma cholestanol was markedly elevated in all patients with a mean of 64 ± 23 μmol/l (35–98 μmol/l, normal range: 2-10 μmol/l) (Additional file 1).
Table 1

Clinical characteristics in a cohort of thirteen patients with CTX

Demographic
 - GenderFemale: 9Male: 4
 - Familial geneticsConsanguinity: 4Affected sibs: 6
Age of onset [median; mean ± SD; range] (years)
 - Diarrhea10/13, neonatal
 - School difficulties11/13 [10; 9.9 ± 3.2; 5–15]
 - Cataract (age of surgery) 11/13 [13; 15.4 ± 13.8; 5–54]
 - Psychiatric symptoms6/13 [15.5; 21.2 ± 11.7; 10–40]
 - Walking difficulties11/13 [20; 21.4 ± 10.3; 12–50]
Neurological examination
 Age at examination [median; mean ± SD; range] (years)30; 33 ± 13.8 (18–60)
  - DysmetriaYes: 7/13
  - TandemUnable: 5/13Abnormal: 7/13Normal: 1/13
  - LL spasticityYes: 6/13
  - UL spasticityYes: 0/13
  - LL reflexes (knee)Increased: 6/13Absent: 3/13Normal: 4/13
  - LL reflexes (ankle)Increased: 5/13Absent: 3/13Normal: 5/13
  - UL reflexesIncreased: 9/13Normal: 4/13
  - Plantar reflexesUpgoing: 7/13Flexor/Indifferent: 6/13
  - RombergPositive: 3/12Negative: 9/12
  - LL proprioceptionDecreased: 10/11Normal: 1/11
  - UL proprioceptionNormal: 11/11
Eye movements
 - PursuitSaccadic: 8/13Normal: 5/13
 - SaccadesDysmetric: 7/13Normal: 6/13
Cognitive dysfunction13/13
 - Delayed cognition10/13
 - Dysexecutive/Decline12/13
Paroxysmal manifestations
 - Myoclonic dystonia7/13
 - Epilepsy1/13
Osteoporosis4/13
Tendon Xanthoma3/13
Peripheral neuropathy10/13 - Axonal (4/10), Demyelinating (5/10), Mixed (1/10)
Brain MRI/MRS
 - Global atrophy3/13
 - Periventricular T2 hyperintensities10/13
 - Increased choline peak (MRS)13/13
 - Dentate nuclei T2 hyperintensities12/13
 - Cerebellar atrophy7/13
Fig. 1

Kaplan–Meier analyses indicate the natural history of thirteen patients with CTX for time to diarrhea, cataract, school difficulties, walking difficulty and psychiatric symptoms

Clinical characteristics in a cohort of thirteen patients with CTX Kaplan–Meier analyses indicate the natural history of thirteen patients with CTX for time to diarrhea, cataract, school difficulties, walking difficulty and psychiatric symptoms A detailed neurological evaluation was performed at a median age of 30 years (18–60). Except for two patients with no overt motor dysfunction, CTX patients presented mainly with cerebello-pyramidal (6/13), neuropathic (3/13), cerebellar (1/13) or pyramidal (1/13) dysfunction. Seven patients also displayed postural myoclonic jerks associated with dystonia, including six that were confirmed by electrophysiological recordings [5]. Cognitive functions were altered in all patients and a neuropathy was documented in ten patients (Table 1). On clinical examination, only 3/13 patients had clinical tendon xanthomas (Table 1). Four patients developed osteopenia but none experienced cardiac or pulmonary manifestations (Table 1). Typically, brain MRI showed T2-weighted hyperintensities of the dentate nuclei and brain MR spectroscopy identified an increased peak of choline in all patients (Table 1).

Discussion

We describe the natural history of 13 patients with CTX. Chronic diarrhea was the earliest symptom commonly observed in CTX but did not seem to be a main cause for consultation, possibly due to the absence of associated growth retardation [6, 7]. Nonetheless, paediatric gastroenterologists should search for CTX in the context of an early onset diarrhea, especially with a history of infantile hepatic dysfunction. Similarly, the diagnosis of a cataract in a child or an adolescent must lead to measure plasma cholestanol. In our cohort, cataract and school difficulties tended to occur at a similar age suggesting that visual difficulties may contribute to the early cognitive difficulties of some CTX patients. Years after the onset of diarrhea, cataract and/or school difficulties, many patients developed gait abnormalities primarily related to cerebellar and/or pyramidal dysfunction and combined with cognitive dysfunction. About half of our cohort also developed psychiatric symptoms. Tendon xanthomas were rarely found on clinical examination, which emphasizes that their absence should not delay the diagnosis of CTX [6]. Electromyography often revealed a peripheral neuropathy with either an axonal or a demyelinating pattern. Brain MRI also showed T2-weighted hyperintensities of the dentate nuclei and are suggestive of the diagnosis [8]. The increased peak of choline on MR spectroscopy might be useful to monitor response to therapy. It has been shown that non-neurological and neurological manifestations can respond to chenodeoxycholic acid (CDCA) through decreased plasma cholestanol levels [1, 4, 9]. When initiated early, the therapeutic response to CDCA can be dramatic [10, 11]. Therefore, paediatricians must be at the forefront of diagnosing CTX in children with chronic diarrhea and/or cataract and/or learning difficulties. Indeed, such symptoms constitute an important therapeutic window to initiate treatment in patients with CTX before the onset of disabling motor and psychiatric symptoms.

Conclusion

Our work shows that CTX is almost always diagnosed in adults whereas key symptoms occur in childhood and adolescence. Treatment shall be initiated before the onset of disabling motor and psychiatric symptoms.

Consent for publication

Not applicable (manuscript contains no individual person’s data).
  11 in total

1.  Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized.

Authors:  Matthew T Lorincz; Shirley Rainier; Donald Thomas; John K Fink
Journal:  Arch Neurol       Date:  2005-09

2.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Gian Nicola Gallus; Maria Teresa Dotti; Antonio Federico
Journal:  J Inherit Metab Dis       Date:  2014-01-18       Impact factor: 4.982

Review 3.  Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis.

Authors:  A Verrips; B G van Engelen; R A Wevers; B M van Geel; J R Cruysberg; L P van den Heuvel; A Keyser; F J Gabreëls
Journal:  Arch Neurol       Date:  2000-04

4.  Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic Acid.

Authors:  Olivier Bonnot; Matthew J Fraidakis; Raffaella Lucanto; Dominique Chauvin; Nathalie Kelley; Monique Plaza; Odile Dubourg; Olivier Lyon-Caen; Frédéric Sedel; David Cohen
Journal:  CNS Spectr       Date:  2010-04       Impact factor: 3.790

5.  Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study.

Authors:  V M Berginer; J Berginer; A D Korczyn; R Tadmor
Journal:  J Neurol Sci       Date:  1994-03       Impact factor: 3.181

Review 6.  Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy.

Authors:  Antonio Federico; Maria Teresa Dotti
Journal:  J Child Neurol       Date:  2003-09       Impact factor: 1.987

7.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

8.  Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.

Authors:  Vladimir M Berginer; Bella Gross; Khayat Morad; Nechama Kfir; Siman Morkos; Salameh Aaref; Tzipora C Falik-Zaccai
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

Review 9.  Myoclonus and dystonia in cerebrotendinous xanthomatosis.

Authors:  Julien Lagarde; Emmanuel Roze; Emmanuelle Apartis; Deepa Pothalil; Frédéric Sedel; Philippe Couvert; Marie Vidailhet; Bertrand Degos
Journal:  Mov Disord       Date:  2012-10-31       Impact factor: 10.338

Review 10.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

View more
  16 in total

1.  GLUT1 Deficiency in a Patient Diagnosed as Cerebral Palsy: Is NGS a Valuable Tool to Be Considered in All Cases of CP to Detect Underlying Genetic Disorders?

Authors:  Aurélie Méneret; Emmanuel Roze
Journal:  Mov Disord Clin Pract       Date:  2019-03-28

2.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

3.  Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability.

Authors:  Austin Larson; James D Weisfeld-Adams; Tim A Benke; Penelope E Bonnen
Journal:  JIMD Rep       Date:  2016-11-18

4.  The phenotype of adult versus pediatric patients with inborn errors of metabolism.

Authors:  Jean-Marie Saudubray; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-06-06       Impact factor: 4.982

5.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

6.  A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract.

Authors:  Mohamed S Abdel-Hamid; Mahmoud Y Issa; Ghada A Otaify; Maha S Zaki
Journal:  Metab Brain Dis       Date:  2017-02-22       Impact factor: 3.584

Review 7.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

8.  Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis.

Authors:  Christopher D Stephen; David Balkwill; Peter James; Elizabeth Haxton; Kenneth Sassower; Jeremy D Schmahmann; Florian Eichler; Richard Lewis
Journal:  Neurology       Date:  2020-01-21       Impact factor: 9.910

Review 9.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

10.  Familial variability of cerebrotendinous xanthomatosis lacking typical biochemical findings.

Authors:  Adam J Guenzel; Andrea DeBarber; Kimiyo Raymond; Radhika Dhamija
Journal:  JIMD Rep       Date:  2021-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.